Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;10(4):187-91.
doi: 10.7497/j.issn.2095-3941.2013.04.002.

Asian trends in primary androgen depletion therapy on prostate cancer

Hideyuki Akaza  1
Affiliations
Review

Asian trends in primary androgen depletion therapy on prostate cancer

Hideyuki Akaza. Cancer Biol Med. 2013 Dec.

Abstract

There are notable differences in the incidence and mortality rates for prostate cancer between Asia and Western countries. It is also recognized that there are differences in thinking with regard to treatment options. Recently it is also the case that opinions have been reported concerning the differences between Asian and Western patients with regard to their reaction to androgen depletion therapy (ADT). Given that ADT is a method of treatment that focuses on the elimination of testosterone, an inevitable symptom of its administration is testosterone losing syndrome. It is for this reason that in Western countries ADT has only been recommended in cases of advanced or metastatic cancer. On the other hand, in Asia, ADT is used in relatively many cases, including non-metastatic localized cancer and invasive localized cancer. To date, however, there has been little substantive discussion concerning this difference in utilization of ADT. ADT-related drugs for prostate cancer and the development of new drugs for castration resistant prostate cancer (CRPC) have been actively tested in recent years. It could be the case that analyzing the differences in concepts about ADT between Asia and the West could contribute to the effective use of ADT-related drugs and also help to build new treatment strategies for prostate cancer.

Keywords: Androgen depletion therapy; Asia; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

    1. Akaza H, Naito S, Cheng C, Kaisary A, Soebadi DM, Umbas R, et al. Asian trends in prostate cancer hormone therapy. Gan To Kagaku Ryoho 2002;29:1951-1961 - PubMed
    1. Akaza H, Chang SJ, Chen KK, Esuvaranathan K, Fujioka T, Hirao Y, et al. The 2nd conference on Asian trends in prostate cancer hormone therapy. Gan To Kagaku Ryoho 2003;30:1533-1542 - PubMed
    1. Akaza H, Naito S, Chang SJ, Chen KK, Cheng C, Choi HY, et al. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy. Gan To Kagaku Ryoho 2004;31:1285-1295 - PubMed
    1. Akaza H, Moore MA, Chang SJ, Cheng C, Choi HY, Esuvaranathan K, et al. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy. Asian Pac J Cancer Prev 2007;8:3-12 - PubMed
    1. Cheng C, Akaza H, Chen KK, Moore MA, Naito S, Song JM, et al. Prostate cancer control--aims of the UICC Asia Regional Office Consortium. Asian Pac J Cancer Prev 2006;7:350-368 - PubMed

LinkOut - more resources